What is the profile of the diabetic patient in whom the diabetes specialist should strongly consider the LDL-C lowering and outcome-improving effects of PCSK9 inhibitors? How do we risk stratify populations for secondary prevention?

What is the profile of the diabetic patient in whom the diabetes specialist should strongly consider the LDL-C lowering and outcome-improving effects of PCSK9 inhibitors? How do we risk stratify populations for secondary prevention?

What is the profile of the diabetic patient in whom the diabetes specialist should strongly consider the LDL-C lowering and outcome-improving effects of PCSK9 inhibitors? How do we risk stratify populations for secondary prevention?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Lawrence Leiter, MD, FRCP(C), FACP

Lawrence Leiter, MD, FRCP(C), FACP

Head, Division of Endocrinology and Metabolism
Director, Lipid Clinic
Associate Director, Clinical Nutrition and Risk Factor Modification Centre
St. Michael’s Hospital
Professor of Medicine and Nutritional Sciences
University of Toronto
Toronto, Ontario